Clinical trial
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus…
NCT00312286 · Takeda, Industry · Terminated
Key facts
| NCT number | NCT00312286 |
|---|---|
| Title | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. |
| Official title | A Randomized, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection |
| Lead sponsor | Takeda, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Papillomavirus Infections |
| Intervention type | Drug |
| Interventions | 851B |
| Enrollment | 538 |
| Start date | Apr 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Apr 10, 2006 |
| Last update posted | Sep 23, 2016 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: